Sii Investments Inc. WI reduced its position in Gilead Sciences Inc. (NASDAQ:GILD) by 4.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,107 shares of the biopharmaceutical company’s stock after selling 1,950 shares during the period. Sii Investments Inc. WI’s holdings in Gilead Sciences were worth $3,187,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of GILD. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock valued at $2,220,410,000 after buying an additional 1,023,299 shares during the period. Temasek Holdings Private Ltd raised its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the period. Parnassus Investments CA raised its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock worth $705,774,000 after buying an additional 2,640,284 shares during the period. Finally, Bank of Montreal Can acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $427,750,000. 77.94% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.3883% during mid-day trading on Wednesday, reaching $77.5399. The company had a trading volume of 908,315 shares. The stock has a market capitalization of $102.33 billion, a PE ratio of 6.8053 and a beta of 1.10. The company’s 50-day moving average is $79.28 and its 200-day moving average is $85.29. Gilead Sciences Inc. has a one year low of $76.67 and a one year high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Zacks’ consensus estimate of $3.02 by $0.06. The business had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm’s revenue was down 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.15 earnings per share. Equities research analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.43%. Gilead Sciences’s dividend payout ratio is presently 16.56%.
GILD has been the topic of a number of research reports. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, June 8th. Leerink Swann reiterated a “buy” rating and issued a $120.00 price target (down from $123.00) on shares of Gilead Sciences in a research report on Thursday, June 9th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, June 13th. Jefferies Group reissued a “hold” rating and issued a $96.00 price objective on shares of Gilead Sciences in a research note on Sunday, June 12th. Finally, Morgan Stanley reissued a “hold” rating and issued a $103.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 15th. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $104.63.
In related news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total value of $409,200.00. Following the transaction, the executive vice president now owns 132,964 shares of the company’s stock, valued at $10,881,773.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kevin E. Lofton sold 3,500 shares of the stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.